DETECTION AND COMMUNICATION OF CONCOMITANT USE OF CAPECITABINE AND PROTON PUMP INHIBITORS (submitted in 2019)
4CPS-076
INDIRECT COMPARISON BETWEEN PEMBROLIZUMAB MONOTHERAPY AND PEMBROLIZUMAB CHEMOTHERAPY REGIMENE IN SQUAMOUS LUNG CANCER (submitted in 2019)
4CPS-075
IBRUTINIB ASSOCIATED ATRIAL FIBRILLATION: INCIDENCE AND MANAGEMENT IN THE REAL LIFE CLINICAL SETTING (submitted in 2019)
4CPS-074
CYCLIN DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER: POTENTIAL DRUG INTERACTIONS (submitted in 2019)
4CPS-073
EFFECTIVENESS AND SAFETY OF PLATIN/PERMETREXED COMBINATION IN NON-SMALL CELL LUNG CANCER. (submitted in 2019)
4CPS-072
COMPARISON OF IMMUNE CHECKPOINT INHIBITORS (NIVOLUMAB, PEMBROLIZUMAB, ATÉZOLIZUMAB AND DURVALUMAB) IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER: TOLERANCE AND FINANCIAL IMPACT (submitted in 2019)
4CPS-071
ANALYSIS OF EFFECTIVENESS: USE OF PERTUZUMAB AND TRASTUZUMAB IN NEOADJUVANT TREATMENT IN PATIENTS WITH HER2 POSITIVE BREAST CANCER AND ITS CORRELATION WITH PLASMA LEVELS OF TRASTUZUMAB (submitted in 2019)
4CPS-070
ANALYSIS OF THE USE OF NON-SPECIFIC INTRAVENOUS IMMUNOGLOBULINS IN A TERTIARY HOSPITAL. (submitted in 2019)
4CPS-069
EVALUATION OF PALIVIZUMAB AS PROPHYLAXIS AGAINST RESPIRATORY SYNCYTIAL VIRUS INFECTION (submitted in 2019)
4CPS-068
EFFECTIVENESS OF DOLUTEGRAVIR AND LAMIVUDINE THERAPY IN A TWO DRUG REGIMEN IN A THIRD LEVEL HOSPITAL. (submitted in 2019)
4CPS-067
ANALYSIS OF USAGE OF DIRECT ACTIN ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C. (submitted in 2019)
4CPS-066
CHANGING FROM COBICISTAT TO A RITONAVIR BOOSTED REGIMEN IN HIV POSITIVE PATIENTS (submitted in 2019)
4CPS-065
SWITCHING TO EQUIVALENT ALTERNATIVES: ANTIRETROVIRAL OPTIMISATION STRATEGY (submitted in 2019)
4CPS-064
ADHERENCE TO ANTIRETROVIRAL TREATMENT IN PATIENTS WITH HIV (submitted in 2019)
4CPS-063
USE OF OSELTAMIVIR IN THE TREATMENT OF INFLUENZA A (submitted in 2019)
